You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Is Exenatide the Next Big Thing in Parkinson's Disease?

Article type: Research Article

Authors: Simuni, Tanya | Brundin, Patrik;

Affiliations: Northwestern University Feinberg School of Medicine, Chicago, IL, USA | Laboratory for Translational Parkinson's Disease Research, Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USA | Neuronal Survival Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund, Sweden

Note: [] Correspondence to: Tanya Simuni, Northwestern University Feinberg School of Medicine, Abbott Hall, 11th Floor 1126, 710 North Lake Shore Drive, Chicago, IL 60611, USA. Tel.: +312 503 2970; Fax: +312 908 5073; Emails: [email protected]; [email protected] (Patrik Brundin).

DOI: 10.3233/JPD-149001

Journal: Journal of Parkinson's Disease, vol. 4, no. 3, pp. 345-347, 2014

Published: 2014
Get PDF open access

Abstract

A recent study by Aviles-Olmos and colleagues suggests that 12 months of treatment with the glucagon-like peptide-1 receptor agonist exenatide improves motor and cognitive symptoms in Parkinson's disease (PD), and that the effect persists as long as 12 months after termination of the treatment. Due to the lack of a placebo control, one cannot exclude that the observed differences between patients receiving daily injections of exenatide and non-treated controls are due to a placebo effect. We discuss that large group differences in two independent functional measures remain for at least 12 months following the cessation of exenatide treatment and that this warrants a double-blind placebo-controlled trial with exenatide in PD.

Show more